

DANA-FARBER CANCER INSTITUTE

44 BINNEY STREET, BOSTON, MASSACHUSETTS 02115

TEACHING AFFILIATE OF
HARVARD MEDICAL SCHOOL

ROBERT E. STORTI

ASSOCIATE DIRECTOR FOR RESEARCH RESOURCES
617-738-3487

February 18, 1983

Mr. William Walker, Jr.
Materials Licensing Branch
Division of Fuel Cycle and Material Safety
Washington, D.C. 20555

030 29202

Re: Amendment to Materials License #20-09761-01

Dear Sir:

This is to request two amendments to our license for use of an AECL Gammacell 40 irradiator for the irradiation of small animals and biological samples (#20-09761-01):

- 1) Item 1, "Licensee" -- amend to Dana-Farber Cancer Institute.

Effective January 18, 1983, the Sidney Farber Cancer Institute has been renamed the Dana-Farber Cancer Institute in recognition of the long and generous support of the Charles A. Dana Foundation. There are no changes in the administrative or scientific structure of the Institute attendant to this name change.

- 2) Condition 12 -- amend to include Robert W. Finberg, M.D.

Dr. Finberg's Curriculum Vitae and a copy of his certificate for completion of the Study Program in the Safe Use and Handling of Radioactive Materials offered by Harvard University Health Services are attached. In addition, Dr. Finberg currently holds a Permit to Use Radioisotopes issued by the Radiation Safety Committee under Broad License #20-09568-17.

Also included is a check in the amount of \$40.00 for the amendment fee.

If you should require any additional information please contact:


Frank Osborne
Radiation Safety Officer
Children's Hospital Medical Center
300 Longwood Avenue
Radiation Control Unit, Enders SB-22
Boston, MA 02115
(617) 735-7516

8710060573 870505
REG1 LIC30
20-19761-01 PDR

8710060573 9pp

Thank you in advance for your attention to this amendment request.

Sincerely,

A handwritten signature in cursive script, reading "Robert E. Storti". The signature is written in dark ink and is positioned above the printed name and title.

Robert E. Storti
Associate Director for
Research Resources

/eh
Attach.

cc: Dr. Finberg
Dr. Kiskiss

CURRICULUM VITAE

Name: Robert William Finberg
Address: 100 Aldrich Street, Roslindale, MA 02131
Date of Birth: March 23, 1950
Place of Birth: Baltimore, Maryland
Education:

1971 A.B. University of Chicago
1974 M.D. Albert Einstein College of Medicine

Postdoctoral Training:

Internship and Residencies:

1974-1975 Intern in Medicine, Bellevue Hospital, New York
1975-1976 Junior Resident in Medicine, Bellevue Hospital,
New York
1976-1977 Senior Resident in Medicine, Bellevue Hospital,
New York
1979-1980 Fourth Year Resident Physician, Peter Bent Brigham
Hospital

Research Fellowships:

1977-1978 Research Fellow in Pathology, Harvard Medical
School
1978-1979 Research Fellow in Medicine, Harvard Medical
School
1978-1979 Research/Clinical Fellow in Medicine, Brigham &
Women's Hospital
1979-1980 Clinical Fellow in Medicine, Harvard Medical
School

Licensure and Certification

1976 Massachusetts License Registration No. 40199
1976 American Board of Internal Medicine, Candidate
No. 058714
1980 Board Certified - Infectious Diseases, Candidate
No. 058714

Academic Appointments:

1980- Assistant Professor of Medicine, Harvard Medical
School

Hospital Appointments:

1980-1982 Junior Associate in Medicine, Brigham & Women's

1982- Hospital
Associate Physician, Brigham & Women's Hospital
Awards and Honors:

1973 Alpha Omega Alpha
1980-1983 Hartford Foundation Award for the suport of
faculty in scientific research

Editorial Boards:

1982-1985 Infection and Immunity
1982- Infectious Disease Practice

Memberships in Professional Societies:

1974- American Association for the Advancement of Science
1978- American Society of Microbiology
1979- American Society of Immunologists
1979- American College of Physicians
1980- American Federation for Clinical Research
1982- Infectious Disease Society

Major Research and Clinical Interests:

1. Requirements for the induction of T cell immunity
2. The importance of T cells in mammalian responses to viruses
3. The regulatory role of T cells in response to bacterial infections
4. The origins of alloreactivity

Teaching experience:
(Classroom)

1980 Pathophysiology 902 conference leader
1981, 1982 Immunology 700 lecturer
(Clinical) Consult visit in Infectious Disease - Brigham &
1980, 1981 Women's Hospital
1981, 1982 Consult visit in Infectious Disease - Sidney
Farber Cancer Institute
1981, 1982 Ward visit in Medicine - Brigham & Women's
Hospital.

Principal Clinical and Hospital Service Responsibilities:

1980- Visit in Medicine and Infectious Diseases,
Brigham & Women's Hospital
1980-1981 Consultant in Infectious Diseases, Brockton V.A
Hospital
1982- Chief, Infectious Disease Section - Sidney Farber
Cancer Institute

BIBLIOGRAPHY:

Original Reports:

1. Finberg R, Barland P, and Grayzel A. Measurement of complement components in systemic lupus erythematosus by radial immunodiffusion. *Amer J Clin Pathol*. 1976; 67:97-99.
2. Finberg R, Burakoff SJ, Cantor H, and Benacerraf B. Biological significance of alloreactivity. T-cells stimulated by Sendai virus coated syngeneic cells specifically lyse allogeneic target cells. *Proc Natl Acad Sci*. 1978; 75:5145-5149.
3. Burakoff SJ, Finberg R, Glimcher L, Lemonnier F, Benacerraf B, and Cantor H. The biologic significance of alloreactivity. The ontogeny of T cell sets specific for alloantigens or modified self antigens. *Proc Natl Acad Sci*. 1978; 1414-1422.
4. Finberg R, Burakoff SJ, and Mescher M. The induction of virus specific cytotoxic T lymphocytes with solubilized viral and membrane proteins. *J Exp Med*. 1978; 148:1620-1627.
5. Finberg R, Weiner H, Fields BN, Benacerraf B, and Burakoff SJ. The generation of cytolytic T lymphocytes following reovirus infection: Role of the SI gene. *Proc Natl Acad Sci*. 1978; 148:1620-1627.
6. Mescher M, Finberg R, Sherman L, and Burakoff S. Induction of virus specific H-2 restricted murine CTL by liposomes. In: T and B cell Recognition, ed. by E. Vitetta, F. Bach, and B. Bonavida. New York Academic Press. 1979; 623-632.
7. Finberg R, Greene M, Benacerraf B, and Burakoff SJ. Evidence for antigen specific helper T cells in the CTL response. *J Immunol* 1979; 123:1205-1209.
8. Finberg R, Burakoff SJ, Benacerraf B, and Greene MI. Evidence for antigen specific suppressor T cells in the CTL response. *J Immunol*. 1979; 123:1210-1214.
9. Finberg R, Cantor H, Benacerraf B, and Burakoff SJ. The origins of alloreactivity: Differentiation of prekiller cells to viral infection results in alloreactive cytotoxic T lymphocytes. *J Immunol* 1980; 124:1858-1860.
10. Burakoff SJ, Reiss CS, Finberg R, and Mescher M. Cell mediated immunity to viral glycoproteins. *Reviews of Infectious diseases* 1980; 2:62-77.
11. Finberg R, Weiner H, Burakoff SJ, Benacerraf B, and Fields BN. Type specific reovirus antiserum blocks the cytotoxic T cell target cell interaction: Evidence for the association of the viral hemagglutinin of a non-enveloped virus with the cell

surface. Infect Immun 1981; 29:646-699

12. Wolf J, Rubin D, Finberg R, Kauffman RS, Sharpe A, Trier JS, and Fields BN. Intestinal M cells: A pathway for entry of reovirus into the host. Science. 1981; 212:471.
13. Greene MI, Bromberg JS, Nepom J, Finberg R, Rock K, Whitaker R, Germain RN, Fox I, Perry L, Wetzig R, Takaoki M, Nisonoff A, Benacerraf B, and Sy MS. The role of idiotype in guiding cellular responses. In: Immunoglobulin Idiotypes and Their expression, ed. by C. Janeway, E. Sercarz and H. Wigzell. Academic Press, New York, 1981; P. 725-729.
14. Finberg R, and Benacerraf B. Induction, control and consequences of virus specific cytotoxic T cells. Immunol Rev. 1981; 58: 157-180.
15. Letvin NL, Kauffman RS, and Finberg R. T lymphocytes immunity to reovirus: Cellular requirements for generation and role in clearance of primary infections. J Immunol. 1981; 127:2334-2339.
16. Shapiro ME, Burakoff SJ, Benacerraf B, and Finberg R. Ir gene control of the cytolytic T cell response: H-2k mice are low responders to Sendai. J Immunol. 1981; 127:2571-2574.
17. Whitaker RB, Kauffman RS, Che M, and Finberg RW. Cytotoxic T cell hybridomas: Tumor cells capable of lysing virally infected target cells. J. Immunol. 1981; 129:900-903.
18. Takaoki M, Sy M-S, Whitaker R, Nepom J, Finberg R, Germain RN, Nisonoff A, Benacerraf B, and Greene MI. Biological activity of an idiotype-bearing suppressor T cell factor produced by a long-term T cell hybridoma. J Immunol. 1982; 128:49-55.
19. Finberg R, Spriggs DR, and Fields BN. The specificity of virus specific cytotoxic T cells for protein domains. J Immunol. 1982; 129:2235-2241.
20. Greene MI, Ratnofsky S, Takaoki M, Burakoff SJ, Sy, MS, and Finberg R. Antigen specific factors regulate cytotoxic T lymphocyte responses. J Immunol. 1982; 128:1188-1191.
21. Shapiro M, Onderdonk AS, Kasper DL, and Finberg R. Cellular immunity to Bacteroides fragilis capsular polysaccharide. J Exp Med. 1982; 154:1188-1197.
22. Schatten S, Drebin JA, Takaoki M, Carter R, Tominaga A, Abbas AR, Finberg R, and Greene M. Regulation of the immune response to cell surface antigens in ICN-UCLA symposium. New York Academic Press. 1982.
23. Onderdonk AB, Kasper DL, Shapiro ME, and Finberg RW. Role of the capsular polysaccharide of Bacteroides fragilis in pathogenicity Microbiol. Reviews. 1982.

24. Finberg R, Ertl HCJ, and Shapiro ME. Virus-specific cytolytic T cells: Their in vivo function. Survey of Immunologic Research. 1982; 1:248-252.
25. Letvin NL, Kauffman RS, and Finberg R. Characteristics of an adherent virus specific killer cell. J Immunol. 129:2396-2401, 1982.
26. Takaoki M, Tominaga A, Finberg R, Sy MS, Benacerraf B, and Greene MI. I-J related antigen presentation determines genetic restriction in suppressor-cell pathways in azobenzene-sonate-specific delayed-type hypersensitivity and cytolytic T lymphocyte generation. J Exp Med. 1982; 156:1325-1334.
27. Ertl HCJ, Spriggs DR, Nepom JT, Greene MI, Fields WW and Finberg R. Virus specific cytolytic T lymphocytes recognize anti-idiotypic determinants. PNAS 1982; 79:7479-7483.
28. Ertl HCJ, Brown E, and Finberg R. Sendai virus specific T cell clones. II. Induction of interferon production by Sendai virus-specific T helper cell clones. Eur. J. Immunol. 1982; 12:1051-1053.
29. Sy MS, Lee SH, Tsurufuji M, Rock KL, Benacerraf B, and Finberg R. Two distinct mechanisms regulate the in vivo generation of cytotoxic T cells. J Exp Med. 1982; 125:918-923.
30. Kauffman RS, Wolf JL, Finberg R, Trier JS, and Fields BN. The sigma 1 protein determines the extent of reovirus from the gastrointestinal tract of mice. Virology. In press.

Reviews:

1. Finberg R. Cat Scratch Disease. Infectious Disease Practice 1981; 4:1-7.
2. Finberg R. Kawasaki Disease. Infectious Disease Practice 1982; 5:1-7.
3. Finberg R. Toxic Shock Syndrome. Infectious Disease Practice. In press.

HARVARD UNIVERSITY
UNIVERSITY HEALTH SERVICES
ENVIRONMENTAL HEALTH AND SAFETY


40 Oxford Street
Cambridge, Massachusetts 02138
(617) 495-2061

January 3, 1983

TO WHOM IT MAY CONCERN:

This is to certify that Robert Finberg
participated in the STUDY PROGRAM IN THE SAFE USE OF RADIOISOTOPES IN
RESEARCH conducted by Environmental Health & Safety, University Health
Services, and satisfactorily completed a final examination given at the
end of the program.

The program was designed to impart the principles and practice of radiation safety as it concerns the use of radioactive materials. Additionally, it presented elementary information on radioactivity measurement standardization and monitoring techniques, mathematics and calculations basic to the use and measurements of radioactivity, and on biological effects of radiation.



Jacob Shapiro, Ph.D.
Radiation Protection Officer

JS:dp

DANA-FARBER CANCER INSTITUTE INC. STATEMENT OF REMITTANCE

INVOICE DATE	VOUCHER NUMBER	PURCHASE ORDER NO	INVOICE NUMBER			AMOUNT PAID
02 18	42771	0000	FEE	40.00	.00	40.00

VEND 092943 NUCLEAR REG COMM

CHK 0001563

40.00

DANA-FARBER CANCER INSTITUTE INC.
BOSTON, MASSACHUSETTS 02115

001563

6-39
110

PAY TO NUCLEAR REG COMM
THE
ORDER
OF

00000

****40 DOLLARS .00 CENTS

092943	0001563	02	22	83
VENDOR NO.	CHECK NO.	MO	DAY	YR

AMOUNT OF CHECK	
****40.00	
DOLLARS	CENTS

VOID IF NOT CASHED WITHIN 90 DAYS

THE FIRST NATIONAL BANK OF BOSTON
BOSTON, MASSACHUSETTS 02115

AUTHORIZED SIGNATURE

⑈001563⑈ ⑆011000390⑆523⑈6242⑈